BridgeBio Pharma

Rising Global Price Controls And Costs Will Curb Future Prospects

AnalystLowTarget

Not Invested

Consensus Narrative from 21 Analysts

Published

10 Aug 25

Updated

16 Aug 25

AnalystLowTarget's Fair Value

US$41.00

19.2% overvalued

16 Aug

US$48.87

95.6%

-0.08%

95.6%

-0.08%

Author's Valuation

US$41.0

19.2% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$41.0

19.2% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

42.16%

Biotech revenue growth rate

11.91%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.97%

Calculation

US$173.41m

Earnings '28

57.83x

PE Ratio '28

US$10.03b

Market Cap '28

US$10.03b

Market Cap '28

200.89m

No. shares '28

US$49.92

Share Price '28

US$49.92 Share Price '28

Discounted to 2025 @ 6.94% p.a.

US$40.82

Fair Value '25